ATE135216T1 - Verwendung von spiperone-derivate zur immunosuppression - Google Patents

Verwendung von spiperone-derivate zur immunosuppression

Info

Publication number
ATE135216T1
ATE135216T1 AT90913638T AT90913638T ATE135216T1 AT E135216 T1 ATE135216 T1 AT E135216T1 AT 90913638 T AT90913638 T AT 90913638T AT 90913638 T AT90913638 T AT 90913638T AT E135216 T1 ATE135216 T1 AT E135216T1
Authority
AT
Austria
Prior art keywords
immunosuppression
composition
spiperone
mucosal
derivatives
Prior art date
Application number
AT90913638T
Other languages
English (en)
Inventor
Richard J Sharpe
Kenneth A Arndt
Stephen J Galli
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE135216T1 publication Critical patent/ATE135216T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AT90913638T 1989-08-21 1990-08-15 Verwendung von spiperone-derivate zur immunosuppression ATE135216T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39652389A 1989-08-21 1989-08-21
US49474490A 1990-03-16 1990-03-16

Publications (1)

Publication Number Publication Date
ATE135216T1 true ATE135216T1 (de) 1996-03-15

Family

ID=27015537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90913638T ATE135216T1 (de) 1989-08-21 1990-08-15 Verwendung von spiperone-derivate zur immunosuppression

Country Status (9)

Country Link
EP (1) EP0489108B1 (de)
JP (1) JPH05502217A (de)
AT (1) ATE135216T1 (de)
CA (1) CA2065375A1 (de)
DE (1) DE69025943T2 (de)
IE (1) IE903012A1 (de)
NZ (1) NZ234957A (de)
PT (1) PT95058A (de)
WO (1) WO1991002527A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5574041A (en) * 1990-03-16 1996-11-12 Beth Israel Hospital Association Use of spiperone derivatives as immunosuppressant agents
DE69130216T2 (de) * 1990-03-16 1999-03-25 The Beth Israel Hospital Association, Boston, Mass. Verwendung von spiperon als immunsuppressivum und antiinflammatorisches mittel
CA2090688A1 (en) * 1990-09-04 1992-03-05 Thomas Martin Aune Regulation of neoplastic cell proliferation via a novel 5htla receptor
IT1249678B (it) * 1991-07-12 1995-03-09 Ciro Costagliola Collirio per il trattamento della ipertensione oculare
WO1993012789A1 (en) * 1991-12-27 1993-07-08 Beth Israel Hospital Use of spiperone or spiperone derivatives as immunosuppressant agents
US5693645A (en) * 1992-12-23 1997-12-02 Beth Israel Deaconess Medical Center, Inc. Use of spiperone or spiperone derivatives as immunosuppressant agents
ES2201074T3 (es) * 1993-03-26 2004-03-16 Beth Israel Hospital Association Utilizacion topica o sistemica de buspirona o de derivados de esta para el tratamiento de trastornos patologicos asociados con reacciones inmunitarias.
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
DK0729357T3 (da) 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
TW592729B (en) * 1995-04-06 2004-06-21 Janssen Pharmaceutica Nv Rate-controlled transdermal administration of risperidone
WO1996032944A1 (en) * 1995-04-18 1996-10-24 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
CA2240836A1 (en) * 1995-12-21 1997-07-03 Pierre Van Tran Method for treating dermatitis
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US5886003A (en) * 1996-03-25 1999-03-23 Eli Lilly And Company Methods of treating or ameliorating the symptoms of venomous bites and stings
FR2758263B1 (fr) * 1997-01-16 1999-12-17 Oreal Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP2001039875A (ja) * 1999-07-30 2001-02-13 Soutetsu Cho 免疫活性化製剤および免疫活性化方法
AU2002305123B2 (en) * 2001-03-30 2006-10-05 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
EP1534256A4 (de) * 2002-06-17 2007-06-20 Philadelphia Health & Educatio Immunmodulation und wirkung auf die zellprozesse in zusammenhang mit rezeptoren der serotonin-familie und der blut-gehirn-schranke
EP1534313B1 (de) 2002-07-30 2012-10-17 Omeros Corporation Ophthalmologische irrigationslösungen und verfahren
FR2866567A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee
CN1686139B (zh) * 2005-04-30 2012-07-11 福建师范大学 酮色林在治疗炎性疼痛的新型镇痛药中的应用
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
CA2681267C (en) * 2007-04-13 2013-11-19 Southern Research Institute Anti-angiogenic agents and methods of use
NZ706067A (en) * 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2015101839A1 (en) * 2014-01-01 2015-07-09 Avi Dascalu Compositions and methods of treatment for mycosis fungoides
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
RU2740378C1 (ru) * 2020-02-11 2021-01-13 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Лекарственное средство, стимулирующее регенерацию эндотелия легких при хронической обструктивной болезни легких

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2788309A (en) * 1954-09-03 1957-04-09 Ciba Pharm Prod Inc Reserpine composition for parenteral administration
US2854380A (en) * 1955-09-06 1958-09-30 Upjohn Co Aqueous therapeutic composition comprising reserpine, propylene glycol and sorbitol
ES2094718T3 (es) * 1986-09-22 1997-02-01 Janssen Pharmaceutica Nv Antagonistas de la serotonine para el tratamiento de heridas.

Also Published As

Publication number Publication date
NZ234957A (en) 1997-06-24
AU6347790A (en) 1991-04-03
EP0489108A1 (de) 1992-06-10
AU656121B2 (en) 1995-01-27
EP0489108B1 (de) 1996-03-13
WO1991002527A1 (en) 1991-03-07
EP0489108A4 (en) 1992-10-28
JPH05502217A (ja) 1993-04-22
PT95058A (pt) 1991-05-22
DE69025943D1 (de) 1996-04-18
IE903012A1 (en) 1991-02-27
DE69025943T2 (de) 1996-09-19
CA2065375A1 (en) 1991-02-22

Similar Documents

Publication Publication Date Title
DE69025943D1 (de) Verwendung von Spiperone-derivate zur Immunosuppression
PT859596E (pt) Formulacoes em gel contendo factores de crescimento
IT1153909B (it) Polimeri reattivi per la cura di affezioni cutanee
BR9707325A (pt) Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
ATE290397T1 (de) Formulierung fur die wundheilung mit menschlichem plasma fibronektin
BR9809117A (pt) Composição de gel retardado de liberação prolongada, processo de produzir a mesma, formulação farmacêutica,e , processos de tratamento de uma indicação , de uma doença, e de uma inflamação com uma composição de liberação prolongada
ES2029853T3 (es) Un metodo para preparar una base para pomada de gel.
ATE81776T1 (de) Verwendung von chinolon und naphthyridinantibiotika zur herstellung von ophthalmischen arzneimitteln.
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
IE870577L (en) Topical amide preparation
BR0109896A (pt) Composição tópica em gel, curativo de feridas, seu método e uso
PT1140001E (pt) Composicao para tratamento de queimaduras
ES2061509T3 (es) Composicion de interferon leucocitario humano y tratamiento de la piel.
ZA873928B (en) Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease
NO172114C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte bifenyler
IT1158029B (it) Preparato per ridurre traumi dei tessuti in esseri umani o animali e procedeminto per la sua produzione
ES2054652T3 (es) Composicion farmaceutica acuosa.
WO1996032133A3 (de) Konjugat zur behandlung von entzündungs-, infektions- und/oder hauterkrankungen
DE69127767D1 (de) Verwendung von Hexetidin oder dessen Derivaten oder Salzen zur Herstellung einer pharmazeutischen Zusammensetzung für ophthalmische Verwendung
SU1113093A1 (ru) Способ лечени остеомиелита
RU97104977A (ru) Способ лечения трофических язв и длительно незаживающих ран
ZA906582B (en) Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammation,and hyperproliferative conditions using topical preparations of serotonin antagonists
IT1239478B (it) Sale dell'idrocortisone emisuccinato con la clorexidina per l'impiego topico e composizioni farmaceutiche che lo contengono
UA8421A1 (uk) Препарат для лікування опіків, трофічних язв та раневих пошкоджень шкіри віватон-2

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee